Literature DB >> 12000974

Delayed profound thrombocytopenia presenting 7 days after use of abciximab (ReoPro).

Sanjiv Sharma1, Brijesh Bhambi, William Nyitray, Geetanjali Sharma, Shawn Shambaugh, Adrian Antonescu, Pankaj Shukla, Eileen Denny.   

Abstract

A case of a 65-year-old woman presenting with delayed profound thrombocytopenia 7 days after the use of abciximab (ReoPro) in the setting of percutaneous coronary intervention is described. The patient had normal platelet counts for the first 24 hours after the use of abciximab (ReoPro). She presented with petechiae and profound thrombocytopenia 1 week later. The patient was treated successfully with a platelet transfusion and recovered uneventfully. Profound thrombocytopenia occurs acutely within the first few hours after abciximab (ReoPro) use, so this case was unique in that the profound thrombocytopenia presented 1 week after use of abciximab (ReoPro).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12000974     DOI: 10.1177/107424840200700i103

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  2 in total

1.  Prolonged profound abciximab associated immune thrombocytopenia complicated by transient multispecific platelet antibodies.

Authors:  J A G Lown; A S Hughes; P Cannell
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

Review 2.  Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies.

Authors:  Brian A Baldo
Journal:  Antibodies (Basel)       Date:  2022-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.